Legal & General Group
GTBP icon

Legal & General Group’s GT Biopharma GTBP Stock Holding History

Legal & General Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed -$5K – 3578
2022
Q1 		$5K Hold
2
– – ﹤0.01% 3503
2021
Q4 		$6K Hold
2
– – ﹤0.01% 3532
2021
Q3 		$12K Sell
2
-1
-33% -$7.52K ﹤0.01% 3411
2021
Q2 		$39K Buy
+3
New +$31.2K ﹤0.01% 3030

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Atria Wealth Solutions
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Legal & General Group's GTBP Position: Q2 2022 in Review

Legal & General Group sold out of GT Biopharma (GTBP) in Q2 2022, closing a stake of 2 shares — an estimated $5K sold.

Legal & General Group first reported a position in GTBP in Q2 2021 and held it in 4 quarters. The position peaked at $39K in Q2 2021. 39 funds tracked by Wall St. Rank hold GTBP as of Q2 2022.

  • Legal & General Group reported no remaining GT Biopharma position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 2 GT Biopharma shares in Q2 2022, an estimated $5K.
  • Legal & General Group first reported a position in GT Biopharma in Q2 2021 and held it in 4 quarters.
  • Legal & General Group's GT Biopharma position peaked at $39K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.